public BRAFV600EKNotDetectedCRCResult()
{
YellowstonePathology.Business.Test.IndicationColorectalCancer indication = new IndicationColorectalCancer();
this.m_Indication = indication.IndicationCode;
this.m_IndicationComment = indication.Description;
this.m_Interpretation = "The use of monoclonal antibodies such as cetuximab and panitumumab has significantly expanded the treatment " +
"options for patients with metastatic colorectal cancer (CRC). These agents, when used alone or in combination with chemotherapy, selectively inhibit the epidermal " +
"growth factor receptor (EGFR) and thus prevent activation of the RAS-RAF-MAPK pathway that drives tumor growth and progression. Both BRAF and KRAS mutations occur " +
"at a similar stage in the adenoma-carcinoma sequence of colorectal cancers, and recent studies have demonstrated that these mutations are mutually exclusive. Up " +
"to 15% of all metastatic colorectal cancers, a significant percentage of which are negative for activating KRAS mutations, harbor a V600E/K mutation in the BRAF " +
"gene. Both KRAS and BRAF mutations result in constitutive activation of the RAS-RAF-MAPK pathway, leading to uncontrolled proliferation of tumor cells. Tumors " +
"with either KRAS or BRAF mutations exhibit resistance to anti-EGFR therapies and are associated with shorter progression-free and overall survival. Therefore, " +
"testing for the BRAF V600E/K mutation provides useful prognostic information and allows for individualized treatment of patients with metastatic CRC. A 107-base " +
"product indicative of a BRAF V600E/K mutation was NOT detected by high resolution capillary electrophoresis.";
this.m_References = BRAFV600EKResult.ColoRectalCancerReferences;
}
public BRAFV600EKNotDetectedCRCResult()
{
YellowstonePathology.Business.Test.IndicationColorectalCancer indication = new IndicationColorectalCancer();
this.m_Indication = indication.IndicationCode;
this.m_IndicationComment = indication.Description;
this.m_Interpretation = "The use of monoclonal antibodies such as cetuximab and panitumumab has significantly expanded the treatment " +
"options for patients with metastatic colorectal cancer (CRC). These agents, when used alone or in combination with chemotherapy, selectively inhibit the epidermal " +
"growth factor receptor (EGFR) and thus prevent activation of the RAS-RAF-MAPK pathway that drives tumor growth and progression. Both BRAF and KRAS mutations occur " +
"at a similar stage in the adenoma-carcinoma sequence of colorectal cancers, and recent studies have demonstrated that these mutations are mutually exclusive. Up " +
"to 15% of all metastatic colorectal cancers, a significant percentage of which are negative for activating KRAS mutations, harbor a V600E/K mutation in the BRAF " +
"gene. Both KRAS and BRAF mutations result in constitutive activation of the RAS-RAF-MAPK pathway, leading to uncontrolled proliferation of tumor cells. Tumors " +
"with either KRAS or BRAF mutations exhibit resistance to anti-EGFR therapies and are associated with shorter progression-free and overall survival. Therefore, " +
"testing for the BRAF V600E/K mutation provides useful prognostic information and allows for individualized treatment of patients with metastatic CRC. A 107-base " +
"product indicative of a BRAF V600E/K mutation was NOT detected by high resolution capillary electrophoresis.";
this.m_References = BRAFV600EKResult.ColoRectalCancerReferences;
}
